Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Heart Failure Reports
Erschienen in: Current Heart Failure Reports 5/2020

09.08.2020 | Biomarkers of Heart Failure (WH Tang & J Grodin, Section Editors)

Evidence of Clonal Hematopoiesis and Risk of Heart Failure

verfasst von: Peter Bazeley, Rommel Morales, W. H. Wilson Tang

Erschienen in: Current Heart Failure Reports | Ausgabe 5/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Clonal hematopoiesis of indeterminate potential (CHIP) is characterized by persistent clonal expansion of adult hematopoietic stem cells, which has been increasingly found to be associated with cardiovascular disease and adverse outcomes in heart failure. Here we outline emerging studies on the prevalence of CHIP, and its association with cardiovascular and heart disease.

Recent Findings

Previous genomic studies have found CHIP mutations to be associated with increased risks of arterial disease, stroke, and mortality. Murine studies exploring TET2, DNMT3A, and JAK2 mutations have shown changes in cellularity that decrease cardiac function after insult, as well as increase inflammasome activation.

Summary

Mutations in driver genes are associated with worse clinical outcomes in heart failure patients, as a potential result of the proinflammatory selection in clonal hematopoiesis. Advances in the field have yielded therapeutic targets tested in recent clinical studies and may provide a valuable diagnostic of risk in heart failure.
Literatur
1.
Virani SS, Alonso A, Benjamin EJ, et al. Heart disease and stroke statistics-2020 update: a report from the American Heart Association. Circulation. 2020;141:e139–596.PubMed
2.
Dunlay SM, Pereira NL, Kushwaha SS. Contemporary strategies in the diagnosis and management of heart failure. Mayo Clin Proc. 2014;89:662–76.PubMedCrossRef
3.
Agarwal SK, Chambless LE, Ballantyne CM, et al. Prediction of incident heart failure in general practice: the Atherosclerosis Risk in Communities (ARIC) study. Circ Heart Fail. 2012;5:422–9.PubMedPubMedCentralCrossRef
4.
Lewis EF. The hope that early detection can tip the scale towards heart failure prevention. JACC Heart Fail. 2017;5:191–3.PubMedCrossRef
5.
Sun J, Hu J, Luo D, Markatou M, Wang F, Edabollahi S, et al. Combining knowledge and data driven insights for identifying risk factors using electronic health records. AMIA Annu Symp Proc. 2012;2012:901–10.PubMedPubMedCentral
6.
Wang Y, Ng K, Byrd RJ, Hu J, Ebadollahi S, Daar Z, deFilippi C, Steinhubl SR, Stewart WF (2015) Early detection of heart failure with varying prediction windows by structured and unstructured data in electronic health records. Conf Proc . Annu Int Conf IEEE Eng Med Biol Soc IEEE Eng Med Biol Soc Annu Conf 2015:2530–3.
7.
Choi E, Schuetz A, Stewart WF, Sun J. Using recurrent neural network models for early detection of heart failure onset. J Am Med Inform Assoc. 2017;24:361–70.PubMedCrossRef
8.
Skrzynia C, Berg J, Willis M, Jensen B. Genetics and heart failure: a concise guide for the clinician. Curr Cardiol Rev. 2014;11:10–7.CrossRef
9.
Mazzarotto F, Tayal U, Buchan RJ, et al. Reevaluating the genetic contribution of monogenic dilated cardiomyopathy. Circulation. 2020;141:387–98.PubMedPubMedCentralCrossRef
10.
Hershberger RE, Hedges DJ, Morales A. Dilated cardiomyopathy: the complexity of a diverse genetic architecture. Nat Rev Cardiol. 2013;10:531–47.PubMedCrossRef
11.
Watkins H, Ashrafian H, Redwood C. Inherited cardiomyopathies. N Engl J Med. 2011;364:1643–56.PubMedCrossRef
12.
Ackerman MJ, Priori SG, Willems S, et al. HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies: this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Europace. 2011;13:1077–109.PubMedCrossRef
13.
Buniello A, Macarthur JAL, Cerezo M, et al. The NHGRI-EBI GWAS Catalog of published genome-wide association studies, targeted arrays and summary statistics 2019. Nucleic Acids Res. 2019;47:D1005–12.PubMedCrossRef
14.
15.
Shah S, Henry A, Roselli C, et al. Genome-wide association and Mendelian randomisation analysis provide insights into the pathogenesis of heart failure. Nat Commun. 2020;11:163.PubMedPubMedCentralCrossRef
16.
Walsh R, Thomson KL, Ware JS, et al. Reassessment of Mendelian gene pathogenicity using 7,855 cardiomyopathy cases and 60,706 reference samples. Genet Med. 2017;19:192–203.PubMedCrossRef
17.
18.
19.
Mardis ER, Ding L, Dooling DJ, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med. 2009;361:1058–66.PubMedPubMedCentralCrossRef
20.
Steensma DP, Bejar R, Jaiswal S, Lindsley RC, Sekeres MA, Hasserjian RP, et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood. 2015;126:9–16.PubMedPubMedCentralCrossRef
21.
Nowell C. The minute chromosome (Ph1) in chronic granulocytic leukemia. Blut Zeitschrift für die Gesamte Blutforsch. 1962;8:65–6.CrossRef
22.
Busque L, Gilliland DG. X-inactivation analysis in the 1990s: promise and potential problems. Leukemia. 1998;12:128–35.PubMedCrossRef
23.
Patel AP, Natarajan P. A new murine model of clonal hematopoiesis investigates JAK2V617F in heart failure. JACC Basic to Transl Sci. 2019;4:698–700.CrossRef
24.
25.
Sano S, Wang Y, Walsh K. Clonal hematopoiesis and its impact on cardiovascular disease. Circ J. 2019;83:2–11.CrossRef
26.
Gibson CJ, Lindsley RC, Tchekmedyian V, et al. Clonal hematopoiesis associated with adverse outcomes after autologous stem-cell transplantation for lymphoma. J Clin Oncol. 2017;35:1598–605.PubMedPubMedCentralCrossRef
27.
28.
Genovese G, Kähler AK, Handsaker RE, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med. 2014;371:2477–87.PubMedPubMedCentralCrossRef
29.
• Jaiswal S, Fontanillas P, Flannick J, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014;371:2488–98 Key paper showing age-related clonal hematopoiesis with adverse outcomes.PubMedPubMedCentralCrossRef
30.
• Dorsheimer L, Assmus B, Rasper T, et al. Association of mutations contributing to clonal hematopoiesis with prognosis in chronic ischemic heart failure. JAMA Cardiol. 2019;4:25–33 First report of association between patients with chronic ischemic heart failure with clonal hematopoiesis.PubMedCrossRef
31.
Okano M, Bell DW, Haber DA, Li E. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell. 1999;99:247–57.PubMedCrossRef
32.
33.
Norton N, Li D, Rieder MJ, et al. Genome-wide studies of copy number variation and exome sequencing identify rare variants in BAG3 as a cause of dilated cardiomyopathy. Am J Hum Genet. 2011;88:273–82.PubMedPubMedCentralCrossRef
34.
Bonnefond A, Skrobek B, Lobbens S, et al. Association between large detectable clonal mosaicism and type 2 diabetes with vascular complications. Nat Genet. 2013;45:1040–3.PubMedCrossRef
35.
• Jaiswal S, Natarajan P, Silver AJ, et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N Engl J Med. 2017;377:111–21 Key paper linking CHIP with adverse cardiovascular outcomes.PubMedPubMedCentralCrossRef
36.
Dorsheimer L, Assmus B, Rasper T, et al (2019) Hematopoietic alterations in chronic heart failure patients by somatic mutations leading to clonal hematopoiesis. Haematologica haematol.2019.224402.
37.
• Fuster JJ, MacLauchlan S, Zuriaga MA, et al. Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice. Science (80- ). 2017;355:842–7 This is one of the first papers to mechanistically linked TET2 mutations and atherosclerotic development.CrossRef
38.
Sano S, Oshima K, Wang Y, Katanasaka Y, Sano M, Walsh K. CRISPR-mediated gene editing to assess the roles of TET2 and DNMT3A in clonal hematopoiesis and cardiovascular disease. Circ Res. 2018;123:335–41.PubMedPubMedCentralCrossRef
39.
• Sano S, Oshima K, Wang Y, et al. Tet2-mediated clonal hematopoiesis accelerates heart failure through a mechanism involving the IL-1β/NLRP3 Inflammasome. J Am Coll Cardiol. 2018;71:875–86 This papers to mechanistically linked TET2 mutations with heart failure progression and inflammasomes in animal models.PubMedPubMedCentralCrossRef
40.
Quintás-Cardama A, Kantarjian H, Cortes J, Verstovsek S. Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond. Nat Rev Drug Discov. 2011;10:127–40.PubMedCrossRef
41.
James C, Ugo V, Le Couédic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434:1144–8.PubMedCrossRef
42.
Gupta N, Edelmann B, Schnoeder TM, Saalfeld FC, Wolleschak D, Kliche S, et al. JAK2-V617F activates β1-integrin-mediated adhesion of granulocytes to vascular cell adhesion molecule 1. Leukemia. 2017;31:1223–6.PubMedPubMedCentralCrossRef
43.
Edelmann B, Gupta N, Schnoeder TM, et al. JAK2-V617F promotes venous thrombosis through beta-1/beta-2 integrin activation. J Clin Invest. 2018;128:4359–71.PubMedPubMedCentralCrossRef
44.
45.
46.
• Sano S, Wang Y, Yura Y, et al. JAK2V617F-mediated clonal hematopoiesis accelerates pathological remodeling in murine heart failure. JACC Basic to Transl Sci. 2019;4:684–97 This papers to mechanistically linked JAC2 mutations with cardiac remodeling in animal models.CrossRef
47.
48.
Pomerantz BJ, Reznikov LL, Harken AH, Dinarello CA. Inhibition of caspase 1 reduces human myocardial ischemic dysfunction via inhibition of IL-18 and IL-1β. Proc Natl Acad Sci U S A. 2001;98:2871–6.PubMedPubMedCentralCrossRef
49.
50.
51.
Bracey NA, Beck PL, Muruve DA, et al. The Nlrp3 inflammasome promotes myocardial dysfunction in structural cardiomyopathy through interleukin-1β. Exp Physiol. 2013;98:462–72.CrossRefPubMed
52.
Ridker PM, Thuren T, Zalewski A, Libby P. Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J. 2011;162:597–605.PubMedCrossRef
53.
Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377:1119–31.CrossRefPubMed
54.
Abbate A, Van Tassell BW, Biondi-Zoccai G, et al. Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the Virginia Commonwealth University-Anakinra Remodeling Trial (2) (VCU-ART2) pilot study]. Am J Cardiol. 2013;111:1394–400.PubMedPubMedCentralCrossRef
55.
Abbate A, Kontos MC, Grizzard JD, et al. Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] pilot study). Am J Cardiol. 2010;105:1371–1377.e1.PubMedCrossRef
56.
Hasselbalch HC. Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer? Blood. 2012;119:3219–25.PubMedCrossRef
Metadaten
Titel
Evidence of Clonal Hematopoiesis and Risk of Heart Failure
verfasst von
Peter Bazeley
Rommel Morales
W. H. Wilson Tang
Publikationsdatum
09.08.2020
Verlag
Springer US
Erschienen in
Current Heart Failure Reports / Ausgabe 5/2020
Print ISSN: 1546-9530
Elektronische ISSN: 1546-9549
DOI
https://doi.org/10.1007/s11897-020-00476-w

Weitere Artikel der Ausgabe 5/2020

Current Heart Failure Reports 5/2020 Zur Ausgabe

Imaging in Heart Failure (J Schulz-Menger, Section Editor)

Myocardial Involvement in Rheumatic Disorders

Nonpharmacologic Therapy: Surgery, Ventricular Assist Devices, Biventricular Pacing, and Exercise (A Hasan, Section Editor)

Stem Cell Therapy for Chronic and Advanced Heart Failure

Cardiogenic Shock: Progress in Mechanical Circulatory Support (JE Rame, Section Editor)

Mechanical Support in Early Cardiogenic Shock: What Is the Role of Intra-aortic Balloon Counterpulsation?

Comorbidities of Heart Failure (C. Angermann, Section Editor)

Heart Failure–Induced Skeletal Muscle Wasting

Translational Research in Heart Failure (J Backs & M van den Hoogenhof, Section Editors)

Epitranscriptomics in the Heart: a Focus on m6A

Devices (C Veltmann, Section Editor)

Central Sleep Apnea in Patients with Heart Failure—How to Screen, How to Treat

Neu im Fachgebiet Kardiologie

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Strenge Blutdruckeinstellung lohnt auch im Alter noch

30.04.2024 Arterielle Hypertonie Nachrichten

Ältere Frauen, die von chronischen Erkrankungen weitgehend verschont sind, haben offenbar die besten Chancen, ihren 90. Geburtstag zu erleben, wenn ihr systolischer Blutdruck < 130 mmHg liegt. Das scheint selbst für 80-Jährige noch zu gelten.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Dihydropyridin-Kalziumantagonisten können auf die Nieren gehen

30.04.2024 Hypertonie Nachrichten

Im Vergleich zu anderen Blutdrucksenkern sind Kalziumantagonisten vom Diyhdropyridin-Typ mit einem erhöhten Risiko für eine Mikroalbuminurie und in Abwesenheit eines RAS-Blockers auch für ein terminales Nierenversagen verbunden.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise